Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 22, 2005

View Archived Issues

New data on the effects of valopicitabine in hepatitis C

ScFvMA2-TAP: A fusion protein with clot targeting, antiplatelet and fXa inhibitory properties

A novel OM4 Fab antibody displays antithrombotic efficacy with minimal bleeding risk in vivo

Novel conjugate for liver fibrosis

PGX-200097: targeted to treat positive and negative symptoms of schizophrenia

DOR plans U.S. and E.U. submissions for orBec

Canadian clearance for pivotal trial of BST-CarGel

JNJ-5234801 exerts beneficial effects in rodent models of anxiety and alcoholism

Transgene and IAVI sign manufacturing agreement

New TB vaccine begins clinical trials

Preclinical data for ReN-001 stem cell line for stroke

Long-term continuous abstinence data for CYT002-NicQb

Phase II trial assesses leuprolide as adjuvant for melanoma vaccine

Celltrion obtains Asian commercialization rights for IGN-311

Inex to spin off Targeted Immunotherapy assets

Vernalis to acquire Cita NeuroPharmaceuticals

Galenea receives SBIR to develop siRNA products for influenza

PBD-polyamide conjugate interferes with gene expression in NIH3T3 cells

L-117: A novel 5-fluoracil analogue with reduced toxicity

Three new breast cancer trials begin for Modrenal

PF-941222: A novel FAK inhibitor developed by Pfizer

Xenazine receives French marketing approval

BioMimetic's GEM-21S approved for periodontal bone defects

Vantas approved in Denmark for advanced prostate cancer

Effexor XR approved for adults with panic disorder

FDA Advisory Committee confirms safety of Tamiflu in children

New therapeutic agents for skin disorders disclosed in recent patents

Companies patent new agents with possible application in the treatment of neurological disorders

Histamine H1 receptor antagonists for insomnia emerge from Neurocrine R&D

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 23, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 23, 2026.
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...
Neurotrimin unveiled as marker in intellectual disability
BioWorld Science
Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...
Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease
BioWorld Science
Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...